Who is sponsoring NCT02533219?

NCT02533219 is sponsored by Baylor College of Medicine.

What drugs are being tested in NCT02533219?

Interventions in NCT02533219: 18 F-DOPA.

What condition does NCT02533219 study?

NCT02533219 studies Hyperinsulinemic Hypoglycemia, Persistent, Congenital Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI).

Is NCT02533219 still recruiting?

NCT02533219 is currently no longer available. Last updated 7 September 2020.

Last reviewed 2020-09-07 · How we verify

NCT02533219: [18F]-DOPA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia

NO LONGER AVAILABLE Last updated 7 September 2020

What this trial tests

trial testing 18 F-DOPA in Hyperinsulinemic Hypoglycemia, Persistent. No longer available.

Quick facts

Lead sponsor	Baylor College of Medicine
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	1 location across United States

Drugs / interventions tested

18 F-DOPA — full drug profile →

Conditions studied

Hyperinsulinemic Hypoglycemia, Persistent — all drugs for Hyperinsulinemic Hypoglycemia, Persistent →
Congenital Hyperinsulinism — all drugs for Congenital Hyperinsulinism →
Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) — all drugs for Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) →

Sponsor

Baylor College of Medicine

Who can join

Under 64, any sex, with Hyperinsulinemic Hypoglycemia, Persistent or Congenital Hyperinsulinism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to evaluate the utility of \[18F\]-DOPA PET to provide improved presurgical planning and distinguish between focal and diffuse forms of HI. The investigators will perform descriptive analysis, relying on visual analysis to diagnose and localize a focal lesion. Our findings will be compared to surgical histopathology to determine sensitivity and specificity or this technique. The investigators will also track patient surgical outcomes, specifically whether the patient is surgically "cured" or still requires medical management to control residual hypoglycemia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Baylor College of Medicine trials

Trials by the same sponsor.

NCT07513194 — GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT) · Phase 1 · not yet recruiting
NCT05855824 — Toddler Biomarker of Nutrition Study · NA · not yet recruiting
NCT06738628 — Disposable Endoscope Platform in Third Space Endoscopic Procedures · not yet recruiting
NCT06834997 — Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital · Phase 2 · withdrawn
NCT07387614 — WEB-BASED SUPPORT PROGRAM FOR CAREGIVERS OF VETERANS WITH DEMENTIA DISCHARGED FROM SKILLED NURSING FACILITIES TO HOME · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02533219 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baylor College of Medicine
Last refreshed: 7 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02533219.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing